Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Pamela Blair Allen, Ann S. LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 249–251.

https://doi.org/10.1182/hematology.2019000077

Published: 2019

Journal Articles

Novel agents and immune invasion in Hodgkin lymphoma

Reid W. Merryman, Ann LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 243–248.

https://doi.org/10.1182/hematology.2019000029

Published: 2019

Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.

https://doi.org/10.1182/hematology.2019000075

Published: 2019

Journal Articles

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

Alison J. Moskowitz

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 207–212.

https://doi.org/10.1182/asheducation-2018.1.207

Published: 2018

Journal Articles

Fixed duration vs continuous therapy in multiple myeloma

Heinz Ludwig, Niklas Zojer

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 212–222.

https://doi.org/10.1182/asheducation-2017.1.212

Published: 2017

Journal Articles

Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents

Andrés José María Ferreri

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 565–577.

https://doi.org/10.1182/asheducation-2017.1.565

Published: 2017

Journal Articles

Management of multiple myeloma in the newly diagnosed patient

María-Victoria Mateos, Jesús F. San Miguel

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 498–507.

https://doi.org/10.1182/asheducation-2017.1.498

Published: 2017

Journal Articles

Role of stem cell transplant and maintenance therapy in plasma cell disorders

Philip L. McCarthy, Sarah A. Holstein

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 504–511.

https://doi.org/10.1182/asheducation.V2016.1.504.088352

Published: 2016

Journal Articles

Frontline therapy and role of high-dose consolidation in mantle cell lymphoma

Simon Rule

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 419–424.

https://doi.org/10.1182/asheducation-2016.1.419

Published: 2016

Journal Articles

Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment

Eva Hoster, Christiane Pott

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 437–445.

https://doi.org/10.1182/asheducation-2016.1.437

Published: 2016

Journal Articles

Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Craig Moskowitz

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 331–338.

https://doi.org/10.1182/asheducation-2016.1.331

Published: 2016

Journal Articles

Myeloma: management of the newly diagnosed high-risk patient

Angela Dispenzieri

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 485–494.

https://doi.org/10.1182/asheducation-2016.1.485

Published: 2016

Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.

https://doi.org/10.1182/asheducation-2016.1.495

Published: 2016

Journal Articles

Management of adult Ph-positive acute lymphoblastic leukemia

Sabina Chiaretti, Robin Foà

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 406–413.

https://doi.org/10.1182/asheducation-2015.1.406

Published: 2015

Journal Articles

Maintenance therapy for multiple myeloma in the era of novel agents

Thierry Facon

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 279–285.

https://doi.org/10.1182/asheducation-2015.1.279

Published: 2015

Journal Articles

What is the role of autologous transplant for lymphoma in the current era?

Patrick Stiff

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 74–81.

https://doi.org/10.1182/asheducation-2015.1.74

Published: 2015

Journal Articles

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Paul G. Richardson, Jacob P. Laubach, Nikhil C. Munshi, Kenneth C. Anderson

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 255–261.

https://doi.org/10.1182/asheducation-2014.1.255

Published: 2014

Journal Articles

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era

Solomon A. Graf, Ajay K. Gopal

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 151–157.

https://doi.org/10.1182/asheducation-2014.1.151

Published: 2014

Journal Articles

Multiple myeloma: a model for scientific and clinical progress

Jesus San Miguel

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 1–7.

https://doi.org/10.1182/asheducation-2014.1.1

Published: 2014

Journal Articles

All transplantation-eligible patients with myeloma should receive ASCT in first response

Philippe Moreau, Michel Attal

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 250–254.

https://doi.org/10.1182/asheducation-2014.1.250

Published: 2014

NARROW

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Novel agents and immune invasion in Hodgkin lymphoma

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

Fixed duration vs continuous therapy in multiple myeloma

Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents

Management of multiple myeloma in the newly diagnosed patient

Role of stem cell transplant and maintenance therapy in plasma cell disorders

Frontline therapy and role of high-dose consolidation in mantle cell lymphoma

Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment

Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Myeloma: management of the newly diagnosed high-risk patient

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Management of adult Ph-positive acute lymphoblastic leukemia

Maintenance therapy for multiple myeloma in the era of novel agents

What is the role of autologous transplant for lymphoma in the current era?

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era

Multiple myeloma: a model for scientific and clinical progress

All transplantation-eligible patients with myeloma should receive ASCT in first response

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only